Fundraising Fox
🦊/Companies
Sign in

Convergent Therapeutics

Cambridge, US · Founded 2020 · Delaware corporation · 3 known investors

Find your way into Convergent Therapeutics

257 people in our graph share verified history with the Convergent Therapeutics team — schools, employers, funds. One of them is your warm intro.

Dougunlockedknows Alexander Brown · together at University of Wisconsin-Madison (overlapped)
×2knows the team · via University of Wisconsin-Madison
×6knows the team · via Carnegie Mellon University - Tepper School of Business
knows the team · via ARIAD Pharmaceuticals, Inc.
×2knows the team · via EMD Serono, Inc.
Biotech

Founders & leadership

Convergent Therapeutics was founded in 2020 by Philip Kantoff and Neil Bander.

PKPhilip Kantoff
Philip KantoffinCo-founder
NB
Neil BanderCo-founder
ESEric Sullivan
Eric SullivaninExecutive
ABAlexander Brown
Alexander BrowninCOOAlexander Brown is an executive officer at Convergent Therapeutics with more than two decades of experience in drug development and commercialization, with focus areas including immuno-oncology, oncology, and infectious disease.

Board

JSJake Simson
Jake SimsoninBoard directorPartner at RA Capital
TZTal Zaks
Tal ZaksinBoard directorPartner at OrbiMed
JT
Jim TrenkleBoard director

Investors · 3

InvusreportedNew York
OrbiMedreported · 2 sourcesNew York · $1M – $75M
RA Capitalreported · 3 sourcesBostonvia Jake Simson · board

Reported raises · per SEC filings

Form D private placements

$51.4M disclosed across 2 rounds · 2023–2024

▶$22.2MraisedAug 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SullivanExecutive Officer
  • Jake SimsonDirector
  • Tal ZaksDirector
  • Jim TrenkleDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Neil BanderExecutive Officer, Director
Offering amount
$40M
Amount sold
$22.2M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.2MraisedMay 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil BanderDirector
  • Jake SimsonDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Tal ZaksDirector
Offering amount
$99.2M
Amount sold
$29.2M
First sale
Apr 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data - AOLaol.com · Aug 2026Convergent raises $90M to develop its radiopharmaceutical for prostate cancer | BioPharma Divebiopharmadive.com · May 2023Radioantibody startup led by prostate cancer experts raises $90M - Convergent Therapeuticsconvergentrx.com · May 2023Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumorsprnewswire.com · May 2023Radiopharmaceutical company Convergent closes series A to the tune of $90Mfiercebiotech.com · May 2023Convergent Therapeutics Raises $90M in Series A Fundingfinsmes.com · May 2023

Frequently asked questions

Who founded Convergent Therapeutics?
Convergent Therapeutics was founded by Philip Kantoff, Neil Bander in 2020.
Who are Convergent Therapeutics's investors?
Convergent Therapeutics's investors include Invus, OrbiMed, RA Capital.
How much funding has Convergent Therapeutics raised?
Convergent Therapeutics has disclosed $51.4M raised across 2 rounds.
Where is Convergent Therapeutics headquartered?
Convergent Therapeutics is headquartered in Cambridge, US.